Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3130-3137

  Baekken, Morten ^a,b   Os, Ingrid ^a,b   Sandvik, Leiv ^a   Oektedalen, Olav ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Beta 2 microglobulin; Blood pressure; Combination antiretroviral treatment; HIV; Microalbuminuria

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREVALENCE; PRIORITY JOURNAL; URINALYSIS;

ADULT; ALBUMINURIA; BETA 2-MICROGLOBULIN; CASE-CONTROL STUDIES; COHORT STUDIES; CREATININE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NORWAY; TIME FACTORS;

EID: 52449111828     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn236     Document Type: Article

References (44)

1. Palella FJ, Jr, Delaney KM, Moorman AC et al. (HIV Outpatient Study Investigators). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860
2. d'Arminio Monforte A, Sabin CA, Phillips A et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165: 416-423
3. Hicks C, Currier J, Sax P et al. Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. Aids Patient Care STDS 2003; 17: 221-233
4. Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486
5. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003
6. Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44
7. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710
8. Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218-230
9. Valcour VG, Shikuma CM, Shiramizu BT et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 38: 31-36
10. Samaras K, Wand H, Law M et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care 2007; 30: 113-119
11. Baliga RS, Chaves AA, Jing L et al. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005; 289: H1373-H1380
12. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262
13. Schwartz EJ, Szczech LA, Ross MJ et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16: 2412-2420
14. Szczech LA, Gupta SK, Habash R et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66: 1145-1152
15. Franceschini N, Napravnik S, Eron JJ, Jr et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67: 1526-1531
16. Gardner LI, Holmberg SD, Williamson JM et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 203-209
17. Szczech LA, Hoover DR, Feldman JG et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206
18. Valle R, Haragsim L. Nephrotoxicity as a complication of antiretroviral therapy. Advances in Chronic Kidney Disease 2006; 13: 314-319
19. Bruggeman LA, Ross MD, Tanji N et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11: 2079-2087
20. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-35
21. Romundstad S, Holmen J, Kvenild K et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466-473
22. Stuveling EM, Hillege HL, Bakker SJL et al. C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis 2004; 172: 107-114
23. Stehouwer CD, Nauta JJ, Zeldenrust GC et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323
24. Russo LM, Comper WD, Osicka TM. Mechanism of albuminuria associated with cardiovascular disease and kidney disease. Kidney Int-Suppl 2004: S67-S68
25. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2: 581-590
26. Szczech LA, Grunfeld C, Scherzer R et al. Microalbuminuria in HIV infection. AIDS 2007; 21: 1003-1009
27. Kabanda A, Vandercam B, Bernard A et al. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis 1996; 27: 803-808
28. Luke DR, Sarnoski TP, Dennis S. Incidence of microalbuminuria in ambulatory patients with acquired immunodeficiency syndrome. Clin Nephrol 1992; 38: 69-74
29. Kimmel PL, Umana WO, Bosch JP. Abnormal urinary protein excretion in HIV-infected patients. Clin Nephrol 1993; 39: 17-21
30. Han TM, Naicker S, Ramdial PK et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69: 2243-2250
31. Romundstad S, Holmen J, Hallan H et al. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trondelag Health study (HUNT, 1995-97), Norway. J Intern Med 2002; 252: 164-172
32. Pontremoli R, Sofia A, Ravera M et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: a Genoa investigation on complications. Hypertension 1997; 30: 1135-1143
33. Levey AS, Bosch JP, Lewis JB et al. (Modification of Diet in Renal Disease Study Group).Amore accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470
34. Ormaasen V, Bruun JN, Sandvik L et al. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection. Scand J Infect Dis 2003; 35: 383-388
35. Romundstad S, Holmen J, Hallan H et al. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health study (HUNT), Norway. Circulation 2003; 108: 2783-2789
36. Damsgaard EM, Froland A, Jorgensen OD et al. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300
37. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington diabetes survey. Lancet 1988; 2: 530-533
38. Lacey JN, Forbes MA, Waugh MA et al. Serum beta 2-microglobulin and human immunodeficiency virus infection. AIDS 1987; 1: 123-127
39. Festa A, D'Agostino R, Howard G et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int 2000; 58: 1703-1710
40. Gosling P. Microalbuminuria: a marker of systemic disease. Hosp Med 1995; 54: 285-290
41. Saves M, Chene G, Ducimetiere P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298
42. Triant VAa, Grinspoon SKb. Vascular dysfunction and cardiovascular complications. Curr Opin in HIV & AIDS 2007; 2: 299-304
43. Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18
44. Hallan H, Romundstad S, Kvenild K et al. Microalbuminuria in diabetic and hypertensive patients and the general population - consequences of various diagnostic criteria - the Nord-Trondelag Health study (HUNT). Scand J Urol Nephrol 2003; 37: 151-158